Predictive factors of histological response of colorectal liver metastases after neoadjuvant chemotherapy

Table 1 Preoperative criteria

	NR	R	P-value	Total
	N = 76, n (%)	N = 74, n (%)		N = 150, n (%)
Gender
F	33 (43.4)	38 (51.4)	0.33	71 (47.3)
M	43 (56.6)	36 (48.6)		79 (52.7)
Age, in yr
Median	631	641	0.91	63.31
ASA
1	3 (3.9)	4 (5.4)	0.33	7 (4.7)
2	70 (92.1)	70 (94.6)		140 (93.3)
3	3 (3.9)	0 (0)		3 (2)
Number of lesions before treatment
Median	31	31	0.35	31
Bilobar lesions
No	26 (34.2)	30 (40.5)	0.42	56 (37.3)
Yes	50 (65.8)	44 (59.5)		94 (62.7)
Synchronous liver metastases
No	21 (27.6)	17 (23)	0.51	38 (25.3)
Yes	55 (72.4)	57 (77)		112 (74.7)
Metachronous livers metastases
No	55 (72.4)	57 (77)	0.51	112 (74.7)
Yes	21 (27.6)	17 (23)		38 (25.3)
Time period if metachronous, in mo
Median	141	151	0.96	141
Extra-hepatic metastases
N	56 (73.7)	57 (77)	0.63	113 (75.3)
Yes	20 (26.3)	17 (23)		37 (24.7)
Primary cancer
Colon	57 (75.0)	39 (52.7)	0.004	96 (64)
Rectum	19 (25.0)	35 (47.3)		54 (36)
N+ status primary tumor
No	20 (28.2)	27 (37)	0.26	47 (32.6)
Yes	51 (71.8)	46 (63)		97 (67.4)
Cytotoxic chemotherapy
5-FU	72 (94.7)	69 (93.2)	0.74	141 (94)
Oxaliplatin	33 (43.4)	31 (41.9)	0.85	64 (42.7)
Irinotecan	54 (71.1)	54 (73)	0.79	108 (72)
Capecitabine	1 (1.3)	1 (1.4)	1	2 (1.3)
Raltitrexed	0 (0.0)	1 (1.4)	0.49	1 (0.7)
Targeted preoperative therapy
No	24 (31.6)	23 (31.1)	0.95	47 (31.3)
Yes	52 (68.4)	51 (68.9)		103 (68.7)
Type of targeted therapy
None	24 (31.6)	23 (31.1)	0.056	47 (31.3)
Bevacizumab	33 (43.4)	43 (58.1)		76 (50.7)
Cetuximab	17 (22.4)	6 (8.1)		23 (15.3)
Panitumumab	1 (1.3)	2 (2.7)		3 (2)
Aflibercept	1 (1.3)	0 (0)		1 (0.7)
Number of preoperative treatment sessions
Median	8*	6*	0.038	7.5*
Response to preoperative chemotherapy
No	25 (32.9)	13 (17.6)		38 (25.3)
Yes	51 (67.1)	61 (82.4)	0.031	112 (74.7)
Liver-first strategy
No	74 (97.4)	61 (82.4)	0.002	135 (90)
Yes	2 (2.6)	13 (17.6)		15 (10)
Combined surgery
No	72 (94.7)	68 (91.9)	0.53	140 (93.3)
Yes	4 (5.3)	6 (8.1)		10 (6.7)
Two-stage procedure
No	54 (71.1)	60 (81.1)	0.15	114 (76)
Yes	22 (28.9)	14 (18.9)		36 (24)
Repeat hepatectomy
No	63 (82.9)	69 (93.2)	0.051	132 (88)
Yes	13 (17.1)	5 (6.8)		18 (12)
Hepatectomy
Minor	39 (51.3)	33 (44.6)	0.41	72 (48)
Major	37 (48.7)	41 (55.4)		78 (52)

¹Median. NR: Non-responders; R: Responders; F: Female; M: Male; ASA: American Society of Anes-thesiologist’s score; 5-FU: 5-Fluorouracil.